Exploring Alzheimer's Disease Treatment: Established Therapies and Novel Strategies for Future Care DOI
Urvashi Soni, Kuldeep Singh, Divya Jain

и другие.

European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177520 - 177520

Опубликована: Март 1, 2025

Язык: Английский

Synthesis of chiral graphene structures and their comprehensive applications: a critical review DOI
Animesh Sinha, Hongyun So

Nanoscale Horizons, Год журнала: 2024, Номер 9(11), С. 1855 - 1895

Опубликована: Янв. 1, 2024

Chiral graphene, a “superlattice structure,” effectively engages with target substances. Its superconductivity, tunable electronic structure, and topological states could significantly contribute to advanced materials science technologies.

Язык: Английский

Процитировано

4
Alzheimer’s disease and antibody-mediated immune responses to infectious diseases agents: a mendelian randomization study DOI Creative Commons
Jiayuan Zhang, Mingming Wang, Dong Wang

и другие.

Hereditas, Год журнала: 2025, Номер 162(1)

Опубликована: Янв. 4, 2025

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder, with antibody-mediated immune responses to infectious diseases agents potentially playing decisive role in its pathophysiological process. However, the causal relationship between antibodies and AD remains unclear.

Язык: Английский

Процитировано

0
Novel Approaches for Treating Alzheimer’s Disease and Other Dementias DOI
M. Catarina Silva,

David C. Butler,

Sally Temple

и другие.

Oxford University Press eBooks, Год журнала: 2025, Номер unknown, С. 797 - 812

Опубликована: Янв. 1, 2025

Abstract Alzheimer’s disease and disease-related dementias (AD/ADRD) are associated with memory reasoning impairment caused by progressive brain cell death. A common feature is the accumulation of pathological aggregating proteins in neurons glia affected regions, such as extracellular deposition amyloid plaques intracellular tau neurofibrillary tangles. Despite substantial research investment efforts, there no effective disease-modifying or preventative therapeutics for AD/ADRD. Challenges include insufficient understanding pathogenic mechanisms, poor target validation/binding, drug delivery to brain, weak drug-modifier effects. Repeated AD/ADRD clinical trial failures underscore need innovative human cellular preclinical animal models, novel therapeutic modalities, new ways stratify patient populations. In this chapter, progress toward these goals reviewed, including innovations small molecules, biologics, immunotherapies, gene therapies that protein–protein interactions aggregation, promote protein degradation, lessen neuroinflammation, improve blood–brain barrier accessibility.

Язык: Английский

Процитировано

0
Nanoscale drug formulations for the treatment of Alzheimer's disease progression DOI Creative Commons

Liu Liqin,

Haini He,

Bert N. La Du

и другие.

RSC Advances, Год журнала: 2025, Номер 15(6), С. 4031 - 4078

Опубликована: Янв. 1, 2025

Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no effective disease-modifying treatments.

Язык: Английский

Процитировано

0
Exploring Alzheimer's Disease Treatment: Established Therapies and Novel Strategies for Future Care DOI
Urvashi Soni, Kuldeep Singh, Divya Jain

и другие.

European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177520 - 177520

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0